ESR1 and breast carcinoma: It has also been shown to promote the growth of breast cancer cells in estrogen receptor-negative (ER−)/AR-positive (AR+) patients (Gucalp et al., 2013; Cochrane et al., 2014; Kono et al., 2017; Traina et al., 2018; Thorek et al., 2019).